British Journal of Clinical Pharmacology

Drug interactions—information, education, and the British National Formulary
pp. 371-372(2)
Author: Aronson J.K.

Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology
pp. 373-387(15)
Authors: Brink C.B.; Harvey B.H.; Bodenstein J.; Venter D.P.; Oliver D.W.

The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease
pp. 388-392(5)
Authors: Lee D.K.C.; Lipworth B.J.

Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function
pp. 393-401(9)
Authors: Kamerling I.M.C.; van Haarst A.D.; Burggraaf J.; Schoemaker R.C.; de Kam M.L.; Heinzerling H.; Cohen A.F.; Masclee A.A.M.

Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years
pp. 402-411(10)
Authors: Pitsiu M.; Hussein Z.; Majid O.; Aarons L.; de Longueville M.; Stockis A.

Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan
pp. 412-415(4)
Authors: Antila S.; Kivikko M.; Lehtonen L.; Eha J.; Heikkilä A.; Pohjanjousi P.; Pentikäinen P.J.

Population pharmacokinetics of raltitrexed in patients with advanced solid tumours
pp. 416-426(11)
Authors: Blair E.Y.L.; Rivory L.P.; Clarke S.J.; McLachlan A.J.

Blood–brain barrier transport of morphine in patients with severe brain trauma
pp. 427-435(9)
Authors: Ederoth P.; Tunblad K.; Bouw R.; Lundberg C.J.F.; Ungerstedt U.; Nordström C-H.; Hammarlund-Udenaes M.

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
pp. 436-440(5)
Authors: Solas C.; Poizot-Martin I.; Drogoul M-P.; Ravaux I.; Dhiver C.; Lafeuillade A.; Allegre T.; Mokhtari M.; Moreau J.; Lepeu G.; Petit N.; Durand A.; Lacarelle B.

The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
pp. 441-447(7)
Authors: Niemi M.; Kajosaari L.I.; Neuvonen M.; Backman J.T.; Neuvonen P.J.

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese
pp. 448-455(8)
Authors: Fukazawa I.; Uchida N.; Uchida E.; Yasuhara H.

Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline
pp. 456-463(8)
Authors: Davies B.J.L.; Coller J.K.; James H.M.; Gillis D.; Somogyi A.A.; Horowitz J.D.; Morris R.G.; Sallustio B.C.

Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards
pp. 464-472(9)
Authors: Davies S.J.C.; Eayrs S.; Pratt P.; Lennard M.S.

Database analyses for the prediction of in vivo drug–drug interactions from in vitro data
pp. 473-486(14)
Authors: Ito K.; Brown H.S.; Houston J.B.

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
pp. 487-494(8)
Authors: Yasui-Furukori N.; Takahata T.; Nakagami T.; Yoshiya G.; Inoue Y.; Kaneko S.; Tateishi T.

Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females
pp. 495-499(5)
Authors: Wenk M.; Todesco L.; Krähenbühl S.

Acute otitis media in children: a retrospective analysis of physician prescribing patterns
pp. 500-505(6)
Authors: Quach C.; Collet J-P.; LeLorier J.

Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine
pp. 506-512(7)
Authors: van Riemsdijk M.M.; Sturkenboom M.C.J.M.; Ditters J.M.; Tulen J.H.M.; Ligthelm R.J.; Overbosch D.; Stricker B.H.

A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals
pp. 513-521(9)
Authors: Dooley M.J.; Allen K.M.; Doecke C.J.; Galbraith K.J.; Taylor G.R.; Bright J.; Carey D.L.

Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants
pp. 522-524(3)
Authors: Visser L.E.; Penning-van Beest F.J.A.; Wilson J.H.P.; Vulto A.G.; Kasbergen A.A.H.; De Smet P.A.G.M.; Hofman A.; Stricker B.H.

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems
pp. 525-528(4)
Authors: Sinzinger H.; O'Grady J.

Protein binding and  :  anomer ratio of dihydroartemisinin in vivo
pp. 529-533(5)
Authors: Batty K.T.; Ilett K.F.; Davis T.M.E.

Notice of future meetings
pp. 534-534(1)